Iconovo
Iconovo is a leading inhalation expert developing new inhaled medicinal products in collaboration with international pharmaceutical companies. They offer patented dry powder inhaler devices and in-house formulation services for both new pharmaceuticals and generic medicines. Their mission is to accelerate access to inhaled therapy by providing innovative, effective, and cost-efficient inhalation platforms, supporting pharmaceutical companies in bringing inhaled treatments to market quickly and with lower risk.
Industries
Nr. of Employees
small (1-50)
Patents
Dry powder inhaler comprising a casing with a first casing portion and a second casing portion
US-11607509-B2
View Details
Dry powder inhaler comprising a casing with a first casing portion and a second casing portion
US-11607509-B2
View DetailsProducts
Family of dry powder inhaler platforms
A set of differentiated dry powder inhaler platforms covering single‑use, pre‑metered and nasal delivery formats, engineered to be low cost to manufacture and to protect moisture‑sensitive payloads.
ICOcap
A robust, capsule based dry powder inhaler with a unique, grip-friendly, hinge design that ensures ease of use. It is immediately available for quick product launch and competitively priced off-the-shelf supply.
ICOone
ICOone is an ultra-low cost, single-dose disposable dry powder inhaler for simple, cost-effective and discreet use. It is simple to carry, intuitive to use and ideal for short-term treatments that only require a few doses for full effect.
ICOpre
ICOpre is a pre-metered dry powder inhaler with a unique design featuring Open-Inhale-Close user operation and 30 individually sealed doses for a month's supply.
ICOres
Flexible multi-dose dry powder inhaler with feedback features, dual reservoirs, and pre-filled with up to 180 doses.
Family of dry powder inhaler platforms
A set of differentiated dry powder inhaler platforms covering single‑use, pre‑metered and nasal delivery formats, engineered to be low cost to manufacture and to protect moisture‑sensitive payloads.
ICOcap
A robust, capsule based dry powder inhaler with a unique, grip-friendly, hinge design that ensures ease of use. It is immediately available for quick product launch and competitively priced off-the-shelf supply.
ICOone
ICOone is an ultra-low cost, single-dose disposable dry powder inhaler for simple, cost-effective and discreet use. It is simple to carry, intuitive to use and ideal for short-term treatments that only require a few doses for full effect.
ICOpre
ICOpre is a pre-metered dry powder inhaler with a unique design featuring Open-Inhale-Close user operation and 30 individually sealed doses for a month's supply.
ICOres
Flexible multi-dose dry powder inhaler with feedback features, dual reservoirs, and pre-filled with up to 180 doses.
Services
Complete development from customer drug substance to finalized inhalation product including device, formulation, analytical testing and regulatory documentation.
Development of dry powder formulations for small molecules and biologics, optimized for specific inhaler platforms and stability requirements.
Analytical method development, qualification and testing to support formulation development, stability studies and release testing.
Advice on inhalation strategy, licensing models, commercialization pathways and partner identification.
Granting of technology access rights and licensing agreements for substance‑inhaler combinations, including milestone and royalty structures.
Production of clinical trial material for phase I studies and technical support for transferring manufacturing processes to third‑party manufacturers.
Complete development from customer drug substance to finalized inhalation product including device, formulation, analytical testing and regulatory documentation.
Development of dry powder formulations for small molecules and biologics, optimized for specific inhaler platforms and stability requirements.
Analytical method development, qualification and testing to support formulation development, stability studies and release testing.
Advice on inhalation strategy, licensing models, commercialization pathways and partner identification.
Granting of technology access rights and licensing agreements for substance‑inhaler combinations, including milestone and royalty structures.
Production of clinical trial material for phase I studies and technical support for transferring manufacturing processes to third‑party manufacturers.
Expertise Areas
- Inhalation product development
- Dry powder formulation for pulmonary and nasal delivery
- Device engineering and mechanical design for inhalers
- Analytical method development and validation for inhalation products
Key Technologies
- Dry powder inhaler platforms
- Pre‑metered and single‑use inhaler designs
- Dry powder formulation for peptides and biologics
- Aerosol physics and inhaler performance testing
News & Updates
Johan Wäborg, CEO of Iconovo, presented the company at Redeye Investor Forum in Gothenburg, Sweden.
Johan Wäborg, CEO, presented the company at Carnegie's small companies day.
Fredrik Radencrantz, Director Business Development, attended the CPHI Frankfurt event to discuss inhalation development.
Iconovo showcased the ICOpre inhaler platform at the RDD congress.
Iconovo announced an extension of its agreement with Amneal for a generic version of Symbicort.
The US Patent and Trademark Office issued an intention to approve a patent for the ICOone inhaler platform.
Johan Wäborg, CEO of Iconovo, presented the company at Redeye Investor Forum in Gothenburg, Sweden.
Johan Wäborg, CEO, presented the company at Carnegie's small companies day.
Fredrik Radencrantz, Director Business Development, attended the CPHI Frankfurt event to discuss inhalation development.
Iconovo showcased the ICOpre inhaler platform at the RDD congress.
Iconovo announced an extension of its agreement with Amneal for a generic version of Symbicort.
The US Patent and Trademark Office issued an intention to approve a patent for the ICOone inhaler platform.